Peptide-Coated Nanoparticles for Cancer Targeting

Peptide Drug Delivery for Cancer

10x more drug

Delivered to brain tumors by a tumor-homing tetrapeptide-coated nanoparticle compared to non-targeted nanoparticles in a glioblastoma mouse model.

Kang et al., Nanoscale Horizons, 2020

Kang et al., Nanoscale Horizons, 2020

View as image

Chemotherapy kills cancer cells, but it also kills healthy cells. The difference between a toxic drug and a cancer treatment is where the drug ends up. Peptide-coated nanoparticles aim to solve this targeting problem by decorating drug-carrying particles with short peptide sequences that recognize and bind to molecules overexpressed on tumor cells or tumor blood vessels. The peptide finds the tumor. The nanoparticle delivers the drug. The result, in animal models at least, is more drug at the tumor and less everywhere else. This approach has produced striking preclinical results but has not yet yielded an approved cancer therapy. This article examines the peptide targeting strategies, the nanoparticle platforms, and the gap between animal data and clinical translation. For the broader nanoparticle delivery landscape in cancer, see Peptide-Targeted Liposomes: Wrapping Drugs in Tumor-Seeking Bubbles.

How Peptide Targeting Works

The surface of a nanoparticle determines where it goes in the body. Uncoated nanoparticles accumulate in the liver and spleen. PEG-coated nanoparticles circulate longer but distribute nonspecifically. Peptide-coated nanoparticles add a targeting layer: short peptide sequences (typically 3-20 amino acids) that bind receptors overexpressed on cancer cells, tumor vasculature, or the tumor microenvironment.

The targeting peptide serves two functions. First, it concentrates the nanoparticle at the tumor by providing selective binding. Second, in some designs, it triggers internalization, pulling the nanoparticle into the cancer cell where it can release its drug payload directly into the cytoplasm.

The most commonly used targeting peptides fall into three categories:

Integrin-binding peptides (RGD family). The tripeptide RGD (Arg-Gly-Asp) binds alpha-v-beta-3 and alpha-v-beta-5 integrins, which are overexpressed on tumor endothelium and many solid tumor cells. Cyclic RGD variants (cRGD) have higher binding affinity and stability than linear RGD. These peptides direct nanoparticles to tumor blood vessels, where the drug can extravasate into the tumor.

Tumor-penetrating peptides (iRGD, LyP-1). iRGD (CRGDKGPDC) combines integrin binding with a second function: after binding, proteases in the tumor cleave the peptide, exposing a C-end Rule (CendR) motif that binds neuropilin-1 (NRP-1). NRP-1 activation triggers transcytosis, a process that transports the nanoparticle through endothelial cells and deep into tumor tissue. This addresses a limitation of standard RGD targeting: getting past the first layer of tumor vasculature.^[7]

Organ-specific homing peptides. Wu and colleagues (2023) designed a novel tumor-homing cell-penetrating peptide that targeted tumors with high TGF-beta receptor 3 expression, demonstrating that peptide targeting can be customized for specific tumor phenotypes beyond integrin expression.^[8]

iRGD: The Most Studied Tumor-Penetrating Peptide

Thirumalai and colleagues (2023) reviewed the extensive preclinical literature on iRGD in cancer therapy and identified several key properties that make it the leading tumor-penetrating peptide:^[7]

• iRGD does not show cytotoxicity against healthy cells
• It enhances drug accumulation in tumors when co-administered with free drugs (not just when conjugated to nanoparticles)
• It works across multiple tumor types expressing alpha-v integrins
• The penetration effect is active (transcytosis through NRP-1) rather than passive (EPR effect)

Chen and colleagues (2022) developed iRGD-modified nanoparticles based on a marine sulfated polysaccharide for breast cancer therapy. The iRGD coating increased tumor accumulation and anti-tumor efficiency compared to non-targeted particles.^[6]

Singh and colleagues (2024) conjugated iRGD to camptothecin-loaded nanoparticles for colon cancer and demonstrated enhanced tumor accumulation and anti-tumor activity in vivo.^[9]

Brain Tumors: Where Targeting Matters Most

The blood-brain barrier (BBB) blocks 98% of small molecules and virtually all nanoparticles from entering the brain. For brain tumors like glioblastoma, peptide targeting is not an optimization; it is a prerequisite for any drug delivery.

Kang and colleagues (2020) identified a brain-tumor-homing tetrapeptide that increased nanoparticle delivery to glioblastoma 10-fold compared to non-targeted particles in a mouse model. The peptide-coated nanoparticles extended survival in treated mice.^[3]

The approach exploits a feature of brain tumors: the BBB is partially disrupted at the tumor site, and tumor-specific receptors are accessible from the bloodstream. A peptide that binds these receptors can concentrate nanoparticles at the tumor while the intact BBB prevents drug distribution to healthy brain tissue.

Smart Nanoparticle Design: pH-Responsive and Multi-Functional

The most advanced peptide-nanoparticle systems go beyond simple targeting. They incorporate environmental responsiveness, so the targeting function activates only in the tumor microenvironment.

Juang and colleagues (2019) developed pH-responsive PEG-shedding nanoparticles modified with targeting peptides. In the bloodstream (pH 7.4), a PEG layer shields the targeting peptide, preventing off-target binding and extending circulation time. In the acidic tumor microenvironment (pH 6.5-6.8), the PEG layer detaches, exposing the peptide for tumor cell binding and internalization. The nanoparticles also carried both irinotecan and microRNA for dual therapeutic delivery.^[2]

This "stealth-then-target" design addresses a fundamental tradeoff in nanoparticle engineering: PEG coating extends circulation but reduces cellular uptake; targeting peptides increase cellular uptake but accelerate clearance. pH-responsive shedding gets both benefits sequentially.

Peptide-Nanoparticle Cancer Vaccines

Beyond drug delivery, peptide-coated nanoparticles are being developed as cancer vaccines that train the immune system to attack tumors.

Lynn and colleagues (2020) created peptide-TLR7/8a conjugates that self-assembled into nanoparticles. The peptide component provided the tumor antigen, while the TLR agonist provided the danger signal. The self-assembling design eliminated the need for a separate nanoparticle carrier. In mouse models, the conjugate vaccines enhanced CD8 T cell immunity against tumor antigens, producing tumor rejection in therapeutic settings.^[4]

Hesse and colleagues (2019) tested tumor-peptide-based nanoparticle vaccines in mouse tumor models and demonstrated efficient tumor growth control, establishing that nanoparticle presentation of peptide antigens generates stronger anti-tumor immune responses than free peptide vaccines.^[1]

Gene Silencing with Peptide-Functionalized Nanoparticles

Peptide targeting combined with nucleic acid payloads enables gene-specific cancer therapy.

Dissanayake and colleagues (2025) developed cell-penetrating peptide-functionalized siRNA nanoparticles that knocked down HER2 expression in breast cancer cells. The CPP coating solved two problems simultaneously: it directed the nanoparticles to cancer cells and facilitated endosomal escape of the siRNA cargo inside the cell.^[11]

Priwitaningrum and colleagues (2020) loaded apoptosis-inducing peptides into PLGA nanoparticles and demonstrated anti-tumor effects in vivo, showing that the peptide itself can be both the targeting agent and the therapeutic payload.^[5]

Chen and colleagues (2025) took a creative approach, combining anticancer peptide-loaded nanoparticles with engineered bacteria to create biohybrid delivery systems that activated pyroptosis (inflammatory cell death) for tumor immunotherapy.^[10]

Why No Peptide-Targeted Nanoparticle Is Approved for Cancer

The preclinical data is compelling. The clinical pipeline is thin. Several factors explain the gap:

Manufacturing complexity. Peptide-coated nanoparticles are multi-component systems (drug + carrier + peptide + linker + sometimes PEG + sometimes additional payloads). Characterizing and reproducing these at pharmaceutical scale is orders of magnitude harder than manufacturing a small molecule pill.

The EPR debate. Much of nanoparticle tumor accumulation in mouse models relies on the enhanced permeability and retention (EPR) effect: leaky tumor blood vessels that let nanoparticles through. Human tumors have less predictable EPR, and the effect varies between patients and between different tumors in the same patient. Peptide targeting adds active targeting on top of passive EPR, but if EPR is limited, the peptide-coated particles may not reach the tumor in therapeutic concentrations.

Regulatory hurdles. Multi-component nanomedicines require extensive characterization of each component, their interactions, and batch-to-batch consistency. Regulatory agencies have limited precedent for approving these complex systems.

The antibody-drug conjugate comparison. Antibody-drug conjugates (ADCs) deliver drugs to tumors using monoclonal antibodies as targeting agents. Multiple ADCs are FDA-approved and generating billions in revenue. ADCs have larger binding surfaces and higher target affinity than peptide-coated nanoparticles. The question facing peptide-nanoparticle developers is: what can peptide targeting do that antibodies cannot? The answers include better tissue penetration (peptides are smaller), lower cost (peptide synthesis vs. antibody production), and multi-valent display (thousands of peptides per nanoparticle).

For how the peptide targeting concept applies across delivery platforms, see Self-Assembling Peptide Nanostructures: When the Peptide IS the Nanoparticle.

The Bottom Line

Peptide-coated nanoparticles for cancer combine tumor-targeting peptides (RGD, iRGD, organ-specific homing peptides) with drug-loaded nanoparticle carriers to concentrate chemotherapy at tumors. iRGD adds active tumor penetration through NRP-1-mediated transcytosis. Preclinical results are strong: 10-fold increases in tumor drug delivery, extended survival in glioblastoma models, and enhanced immune responses from peptide-nanoparticle vaccines. No peptide-targeted nanoparticle cancer drug is yet approved, limited by manufacturing complexity, variable EPR effects in human tumors, and competition from antibody-drug conjugates. The technology is closest to clinical translation in brain tumors, where the blood-brain barrier makes peptide targeting a necessity rather than an incremental improvement.

Frequently Asked Questions

What are peptide-coated nanoparticles for cancer?

Peptide-coated nanoparticles are drug-carrying particles decorated with short peptide sequences (3-20 amino acids) that bind receptors on cancer cells or tumor blood vessels. The peptide directs the nanoparticle to the tumor, concentrating the drug payload at the disease site while reducing exposure to healthy tissue. Common targeting peptides include RGD (binds integrins) and iRGD (adds tumor-penetrating function).^[7]

How does iRGD help nanoparticles penetrate tumors?

iRGD (CRGDKGPDC) first binds alpha-v integrins on tumor vasculature. Tumor proteases then cleave the peptide, exposing a CendR motif that activates neuropilin-1 (NRP-1). NRP-1 triggers transcytosis, transporting the nanoparticle through the vessel wall and deep into tumor tissue.^[6] This active penetration mechanism pushes drug beyond the first cell layer, unlike passive accumulation.

Are there any approved peptide-targeted nanoparticle cancer drugs?

No peptide-targeted nanoparticle cancer drug is currently FDA-approved. Several are in preclinical and early clinical development. The barriers include manufacturing complexity, variable tumor vasculature permeability in human patients, and regulatory challenges for multi-component nanomedicines. Antibody-drug conjugates, which use antibodies rather than peptides for targeting, have multiple approved products.

Can peptide nanoparticles cross the blood-brain barrier?

Standard nanoparticles cannot cross the blood-brain barrier, but peptide-coated nanoparticles using brain-tumor-homing peptides have achieved 10-fold increases in drug delivery to glioblastoma in mouse models.^[3] The peptides exploit receptors exposed at the partially disrupted BBB around brain tumors, enabling selective drug delivery that spares healthy brain tissue.

What is the RGD peptide used for in cancer?

The RGD (Arg-Gly-Asp) tripeptide binds alpha-v-beta-3 and alpha-v-beta-5 integrins, which are overexpressed on the blood vessels that feed solid tumors and on many cancer cell surfaces. When attached to nanoparticles, RGD directs the drug carrier to tumor vasculature. Cyclic RGD variants (cRGD) have higher binding affinity and are more commonly used in nanoparticle designs.

How do peptide-nanoparticle cancer vaccines work?

Peptide-nanoparticle vaccines combine tumor antigen peptides with immune-stimulating adjuvants on a nanoparticle platform. The nanoparticle presentation enhances immune recognition. Lynn et al. (2020) created peptide-TLR7/8a conjugates that self-assembled into nanoparticles and enhanced CD8 T cell responses against tumors in mice.^[4] The nanoparticle format mimics the size and surface properties of pathogens, triggering stronger immune activation than free peptides.